Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype.

[1]  M. Gladwin,et al.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions , 2009, American journal of hematology.

[2]  S. Hazen,et al.  Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death , 2009, British journal of haematology.

[3]  C. Schaefer-Prokop,et al.  Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension , 2008, American journal of hematology.

[4]  A. Duits,et al.  Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension , 2008, Haematologica.

[5]  G. Filippatos,et al.  Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases. , 2008, Heart & lung : the journal of critical care.

[6]  A. Duits,et al.  Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis , 2008, American journal of hematology.

[7]  M. Gladwin,et al.  Chronic Hyper-Hemolysis in Sickle Cell Anemia: Association of Vascular Complications and Mortality with Less Frequent Vasoocclusive Pain , 2008, PloS one.

[8]  B. Biemond,et al.  Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice , 2008, Haematologica.

[9]  M. Gladwin,et al.  Sickle cell disease vasculopathy: a state of nitric oxide resistance. , 2008, Free radical biology & medicine.

[10]  M. Gladwin,et al.  Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency , 2008, American journal of hematology.

[11]  E. Terpos,et al.  Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. , 2007, Haematologica.

[12]  T. Teerlink,et al.  HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  M. Gladwin,et al.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. , 2007, Blood reviews.

[14]  Bruce Barton,et al.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. , 2006, JAMA.

[15]  T. Teerlink,et al.  Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. , 2006, Analytical biochemistry.

[16]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[17]  Mark T Gladwin,et al.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. , 2005, Blood.

[18]  Stanley L Hazen,et al.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.

[19]  A. Duits,et al.  Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease , 2005, Annals of Hematology.

[20]  A. Duits,et al.  Evidence for a metabolic shift of arginine metabolism in sickle cell disease , 2004, Annals of Hematology.

[21]  M. Gladwin,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[22]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .

[23]  R. Nijveldt,et al.  Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. , 2002, Analytical biochemistry.

[24]  B. Setty,et al.  Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. , 1999, Blood.

[25]  M. Espeland,et al.  The heart in sickle cell anemia. The Cooperative Study of Sickle Cell Disease (CSSCD). , 1995, Chest.